• Merck published research in Science detailing a large-scale biocatalytic manufacturing method for enlicitide decanoate, its investigational oral PCSK9 inhibitor.
• Process uses a tailored suite of enzymes to assemble peptide fragments, drive coupling, support macrocyclization; crystallization-based purification used to improve scalability versus traditional synthesis.
• Company positioned enlicitide as a macrocyclic peptide candidate that could become first approved oral PCSK9 inhibitor, with manufacturing approach aimed at expanding production feasibility for complex oral macrocyclic peptides.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605071405BIZWIRE_USPR_____20260507_BW354410) on May 07, 2026, and is solely responsible for the information contained therein.